Sermonix Pharmaceuticals Inc is a privately held, Ohio-based biopharmaceutical company with a precision medicine focus for bringing targeted oncology products through development, approval, and commercialization. Sermonix’s lead candidate is oral lasofoxifene. Lasofoxifene is currently under investigation in a phase 2 trial and is thought to be a potent third-generation selective estrogen receptor modulator (SERM) (also known as an estrogen agonist/antagonist) with high affinity for the estrogen receptor 1 (ESR1). Previous clinical development programs have suggested potential benefits to breast, bone, and vaginal tissue. Sermonix is currently focused on the study of lasofoxifene for advanced breast cancer treatment, particularly in patients with locally advanced or metastatic estrogen receptor-positive (ER+)/human epidermal growth factor 2-negative (HER2-) breast cancer who have developed an ESR1 mutation.

Add Attachment

New activity in ESR1 mutations was discovered in the laboratory of Donald McDonnell, MD, at Duke University, and Sermonix has exclusive rights to develop and, if FDA-approved, commercialize lasofoxifene in this important area of unmet medical need.

The company was founded in 2014 by David Portman, MD, a leading clinical researcher and expert in women’s health, sexual medicine and menopause, and SERM therapy.

Visit Sermonix Pharmaceuticals at booth number 307, to learn more about the Elaine clinical development program, and to meet members of the Sermonix team.